Investor Presentaiton
Investor Presentation
First nine months of 2018
Slide 107
Phase 3 extension trial in adults and phase 2 trial in
children for once-weekly somapacitan
Somapacitan IGF-1 levels similar to daily
Norditropin® in REAL 1 phase 3 AGHD trial
Cumulative
frequency
Baseline
Placebo
NorditropinⓇ
somapacitan
Phase 3a AGHD extension trial and phase 2
GHD successfully completed
Completed trial i Extension trial
Trial in planning
100%
80%
60%
40%
20%
REAL 1: Phase 3a,
naïve AGHD
Objective: Efficacy
(truncal fat %)/safety
REAL 3: Phase 2, GHD
Objective: Dose finding
(height velocity)/safety
REAL 4: Phase 3, GHD
Objective: Efficacy
(height velocity)/safety
REAL 5: Phase 3, SGA
Objective: Efficacy
(height velocity)/safety
0%
-3 -2 -1
0
1
2
3
2016
2017
2018
2019
IGF-1 standard deviation score
IGF-1 Insulin-like growth factor 1; AGHD: Adult growth hormone deficiency
Source: Novo Nordisk data on file; REAL 1, NN8640-4054
changing
diabetes®
2020
AGHD: Adult growth hormone deficiency GHD: Growth hormone deficiency; SGA: Small
for gestational age
2021
novo nordiskView entire presentation